LRRK2 and multiple sclerosis: Microarray analysis in mixed glial cultures revealed that several genes altered by PU.1 silencing were also risk variants [30] for other neurological diseases with a microglial-mediated inflammatory component, including Parkinson’s disease (HLA-DRA, HLA-DRB5, GPNMB, and LRRK2) and multiple sclerosis (HLA-DRB1, HLA-DRA, and CXCR4) (Additional file 7: Figure S2).